Welcome to our dedicated page for Intercure Ltd. SEC filings (Ticker: INCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to InterCure Ltd. (INCR) SEC filings, giving investors and analysts a primary source for the company’s regulatory disclosures as a foreign private issuer. InterCure files its annual report on Form 20-F and furnishes interim information on Form 6-K, covering financial performance, corporate actions and material events related to its pharmaceutical cannabis operations.
Through Forms 6-K, InterCure submits press releases, condensed consolidated financial statements and management’s discussion and analysis for periods such as the first half of the year. These filings detail revenue, operating profit, net income or loss, cash positions and non-IFRS measures like Adjusted EBITDA for its cannabis segment. They also describe the impact of external events, including war-related damage to the Nir Oz facility and related compensation from Israeli authorities.
Other 6-K filings address strategic agreements and acquisitions, such as the share purchase agreement to acquire Botanico Ltd. (ISHI) and the investment and collaboration agreements with Cannasoul R&D Ltd. Filings also cover corporate governance matters, including notices and proxy materials for annual general meetings, and disclosures about financing transactions like private placements of ordinary shares and warrants or bank loans.
Stock Titan’s platform surfaces these filings in real time from EDGAR and adds AI-powered summaries that highlight key points from lengthy documents. Users can quickly see the main financial trends, understand the structure of acquisitions and collaborations, and identify risk disclosures without reading every page. In addition, Form 6-K reports related to counterparties, such as restructuring proceedings involving service providers, help readers assess operational and credit exposures within InterCure’s pharmaceutical cannabis business.
InterCure Ltd. announced preliminary 2025 results showing estimated revenue of NIS 265 million, about 11% higher than 2024, and positive Adjusted EBITDA. This marks the company’s twelfth consecutive half-year with positive Adjusted EBITDA and demonstrates continued profitability in its cannabis operations.
Revenue in the second half of 2025 was nearly 20% above the same period a year earlier, supported by the company’s first significant revenues from the German market. InterCure reported cash of NIS 43 million, including restricted cash and deposits, and plans to publish full audited 2025 results in an annual report by the end of April 2026.
InterCure Ltd. (dba Canndoc) reported a potential credit and operational issue related to its service provider Bazelet. The company learned that the Bazelet group of companies, a leading producer of cannabis oil and a key provider of production, EU-GMP-certified export, and Israeli distribution services, has entered restructuring proceedings in an Israeli District Court, including a temporary stay of proceedings.
InterCure holds Bazelet-issued checks totaling approximately NIS 27 million that remain outstanding during this stay, creating exposure to possible non-payment. The company states it is monitoring court developments, intends to pursue legal actions to protect its rights and interests as directed by its board, and is evaluating collaboration with an additional packaging facility to secure alternative service capacity.
InterCure Ltd. reported that it will hold its Annual General Meeting of Shareholders on December 30, 2025 at 4:00 p.m. (Israel time) at the offices of its legal counsel in Tel Aviv, Israel. The company is providing shareholders with a Notice and Proxy Statement describing the proposals to be voted on and the procedures for voting in person or by proxy, together with a Proxy Card that enables holders of ordinary shares to vote without attending the meeting. These materials are furnished as exhibits to the report so shareholders can review the agenda and participate in the decision-making process for the company.
InterCure Ltd. furnished a Form 6-K announcing it issued a press release on November 3, 2025 titled “InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation.” The press release is attached as Exhibit 99.1.
The filing highlights a strategic investment and collaboration framework with Cannasoul, focused on advancing cannabis science and pharmaceutical innovation. Additional details are contained in the attached press release.
InterCure Ltd. furnished a Form 6-K that packages its first-half 2025 financial disclosure materials, including a press release, interim financial statements, and management’s discussion and analysis. The press release headline states that InterCure generated NIS 130 million in revenue in the first half of 2025 and reported positive operating cash flow, indicating that its core operations brought in more cash than they consumed over that period.
The accompanying exhibits include condensed consolidated unaudited interim financial statements and a detailed analysis of financial condition and results of operations as of and for the six months ended June 30, 2025, along with related XBRL data files.
InterCure Ltd. is entering a two-phase acquisition of Israeli cannabis technology and brand company ISHI (Botanico Ltd.) through a share purchase agreement. InterCure will first acquire 50% of ISHI’s fully diluted share capital in exchange for 2,261,345 ordinary shares and 205,710 options, then acquire the remaining 50% for an additional 2,252,317 shares and 204,889 options once ISHI posts three consecutive months of positive operating profitability or after 24 months. The total consideration of 4,513,663 shares and 410,599 options represents about 10% of InterCure’s fully diluted shares immediately before the initial closing. ISHI security holders face Rule 144 restrictions and an extra lock-up limiting sales to up to 33% of InterCure’s prior-day Nasdaq trading volume, and two ISHI founders will join InterCure’s leadership team. The initial closing is expected in the first quarter of 2026, subject to Israeli regulatory approvals, with all securities issued in a private placement exempt from U.S. registration.